Ascendis Pharma (ASND1N) Ratios
Ascendis Pharma Ratios
MX:ASND1N's free cash flow for Q2 2026 was $283.11M. For the 2026 fiscal year, MX:ASND1N's free cash flow was decreased by $-3.24M and operating cash flow was $286.35M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.04 | 1.17 | 0.95 | 1.29 | 8.03 |
| Quick Ratio | 0.76 | 0.84 | 0.67 | 1.11 | 7.28 |
| Cash Ratio | 0.58 | 0.62 | 0.53 | 0.62 | 4.45 |
| Solvency Ratio | -0.14 | -0.28 | -0.48 | -0.68 | -1.83 |
| Operating Cash Flow Ratio | 0.05 | -0.34 | -0.63 | -0.69 | -4.16 |
| Short-Term Operating Cash Flow Coverage | 0.11 | -0.62 | -1.11 | -1.20 | -59.71 |
| Net Current Asset Value | $ -356.25M | $ -224.34M | $ -268.56M | $ 97.08M | $ 604.60M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.67 | 0.73 | 0.90 | 0.57 | 0.19 |
| Debt-to-Equity Ratio | -5.35 | -8.10 | -5.10 | 2.35 | 0.24 |
| Debt-to-Capital Ratio | 1.23 | 1.14 | 1.24 | 0.70 | 0.19 |
| Long-Term Debt-to-Capital Ratio | 1.73 | 1.41 | 2.88 | 0.27 | 0.10 |
| Financial Leverage Ratio | -8.00 | -11.16 | -5.67 | 4.14 | 1.23 |
| Debt Service Coverage Ratio | -0.22 | -0.53 | -0.90 | -1.20 | -33.40 |
| Interest Coverage Ratio | -1.69 | -4.26 | -10.34 | -18.31 | -115.52 |
| Debt to Market Cap | 0.08 | 0.11 | 0.10 | 0.08 | 0.02 |
| Interest Debt Per Share | 15.66 | 15.93 | 13.98 | 11.56 | 3.90 |
| Net Debt to EBITDA | -2.33 | -1.02 | -0.85 | -0.33 | 0.65 |
| Profitability Margins | |||||
| Gross Profit Margin | 85.08% | 87.83% | 83.36% | 76.28% | 54.71% |
| EBIT Margin | -18.33% | -84.63% | -161.25% | -1069.17% | -4886.00% |
| EBITDA Margin | -15.87% | -79.76% | -154.16% | -1034.07% | -4688.12% |
| Operating Profit Margin | -18.92% | -76.66% | -170.79% | -1097.85% | -5808.59% |
| Pretax Profit Margin | -29.53% | -102.64% | -177.77% | -1129.12% | -4936.28% |
| Net Profit Margin | -31.67% | -103.97% | -180.51% | -1139.63% | -4931.56% |
| Continuous Operations Profit Margin | -31.67% | -103.97% | -180.51% | -1139.63% | -4931.56% |
| Net Income Per EBT | 107.23% | 101.30% | 101.54% | 100.93% | 99.90% |
| EBT Per EBIT | 156.05% | 133.89% | 104.08% | 102.85% | 84.98% |
| Return on Assets (ROA) | -16.82% | -32.05% | -58.32% | -53.52% | -35.36% |
| Return on Equity (ROE) | 134.58% | 357.68% | 330.44% | -221.45% | -43.41% |
| Return on Capital Employed (ROCE) | -56.16% | -102.63% | -511.40% | -150.64% | -45.89% |
| Return on Invested Capital (ROIC) | -18.19% | -36.53% | -86.85% | -70.25% | -45.20% |
| Return on Tangible Assets | -16.87% | -32.16% | -58.63% | -53.76% | -35.53% |
| Earnings Yield | -1.99% | -4.91% | -7.51% | -9.12% | -5.92% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.39 | 2.19 | 7.43 | 4.30 | 3.54 |
| Payables Turnover | 1.14 | 0.46 | 0.47 | 0.12 | 0.06 |
| Inventory Turnover | 0.34 | 0.15 | 0.21 | 0.09 | 0.05 |
| Fixed Asset Turnover | 4.72 | 3.68 | 2.41 | 0.40 | 0.06 |
| Asset Turnover | 0.53 | 0.31 | 0.32 | 0.05 | 0.01 |
| Working Capital Turnover Ratio | 7.18 | 6.10 | 3.09 | 0.11 | 0.01 |
| Cash Conversion Cycle | 828.84 | 1809.85 | 989.36 | 976.35 | 1759.67 |
| Days of Sales Outstanding | 83.18 | 166.90 | 49.09 | 84.95 | 103.24 |
| Days of Inventory Outstanding | 1066.23 | 2437.92 | 1717.76 | 3929.77 | 7812.33 |
| Days of Payables Outstanding | 320.56 | 794.97 | 777.49 | 3038.37 | 6155.89 |
| Operating Cycle | 1149.40 | 2604.82 | 1766.85 | 4014.72 | 7915.57 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.85 | -5.29 | -8.30 | -8.84 | -7.63 |
| Free Cash Flow Per Share | 0.72 | -5.31 | -8.35 | -9.10 | -8.07 |
| Dividend Paid and CapEx Coverage Ratio | 6.35 | -214.57 | -191.38 | -34.21 | -17.23 |
| Capital Expenditure Coverage Ratio | 6.35 | -214.57 | -191.38 | -34.21 | -17.23 |
| Operating Cash Flow Coverage Ratio | 0.06 | -0.36 | -0.63 | -0.80 | -1.99 |
| Operating Cash Flow to Sales Ratio | 0.07 | -0.84 | -1.75 | -9.69 | -53.70 |
| Free Cash Flow Yield | 0.40% | -4.00% | -7.32% | -7.98% | -6.82% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -50.13 | -20.36 | -13.32 | -10.97 | -16.89 |
| Price-to-Sales (P/S) Ratio | 15.90 | 21.17 | 24.05 | 124.97 | 833.09 |
| Price-to-Book (P/B) Ratio | -67.58 | -72.81 | -44.02 | 24.28 | 7.33 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 252.17 | -25.02 | -13.65 | -12.54 | -14.66 |
| Price-to-Operating Cash Flow Ratio | 212.47 | -25.14 | -13.72 | -12.90 | -15.51 |
| Price-to-Earnings Growth (PEG) Ratio | 1.13 | 0.86 | 0.75 | -0.23 | 1.09 |
| Enterprise Value Multiple | -102.51 | -27.56 | -16.45 | -12.41 | -17.12 |
| Enterprise Value | 11.26B | 7.99B | 6.76B | 6.57B | 6.24B |
| EV to EBITDA | -102.51 | -27.56 | -16.45 | -12.41 | -17.12 |
| EV to Sales | 16.27 | 21.98 | 25.36 | 128.35 | 802.71 |
| EV to Free Cash Flow | 258.03 | -25.99 | -14.40 | -12.87 | -14.13 |
| EV to Operating Cash Flow | 217.41 | -26.11 | -14.47 | -13.25 | -14.95 |
| Tangible Book Value Per Share | -2.75 | -1.90 | -2.67 | 4.61 | 16.04 |
| Shareholders’ Equity Per Share | -2.69 | -1.83 | -2.59 | 4.70 | 16.13 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.07 | -0.01 | -0.02 | -0.01 | 0.00 |
| Revenue Per Share | 11.41 | 6.28 | 4.74 | 0.91 | 0.14 |
| Net Income Per Share | -3.61 | -6.53 | -8.55 | -10.40 | -7.00 |
| Tax Burden | 1.07 | 1.01 | 1.02 | 1.01 | 1.00 |
| Interest Burden | 1.61 | 1.21 | 1.10 | 1.06 | 1.01 |
| Research & Development to Revenue | 0.41 | 0.84 | 1.55 | 7.42 | 38.04 |
| SG&A to Revenue | 0.63 | 0.78 | 0.97 | 4.22 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.26 | 0.25 | 1.25 | 8.59 |
| Income Quality | -0.24 | 0.81 | 0.97 | 0.85 | 1.09 |
Currency in EUR
